Health
GSK to Pay CureVac Up to €1.4 Billion for Flu, Covid Shots
- CureVac plans to refocus on its mRNA cancer vaccines
- The German biotech will shed 30% of its staff in a restructure
GSK is seeking to beef up its vaccine portfolio following the successful launch of its RSV shot Arexvy.
Photographer: Hannah Beier/BloombergThis article is for subscribers only.
GSK Plc agreed to pay as much as €1.4 billion ($1.5 billion) for the full rights to mRNA flu and Covid-19 shots it was developing with CureVac NV as the German biotech refocuses on cancer vaccines.
The partners are restructuring their collaboration, with GSK securing the right to develop, make and sell the vaccines, including potential combinations. CureVac will receive a €400 million initial payment and up to €1.05 billion in milestone payments, plus tiered royalties, the companies said Wednesday.